{"id":42335,"date":"2025-09-26T14:00:56","date_gmt":"2025-09-26T06:00:56","guid":{"rendered":"https:\/\/flcube.com\/?p=42335"},"modified":"2025-09-26T14:00:57","modified_gmt":"2025-09-26T06:00:57","slug":"sichuan-biokin-secures-second-breakthrough-therapy-designation-for-izalontamab-brengitecan-in-advanced-urothelial-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42335","title":{"rendered":"Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma"},"content":{"rendered":"\n<p><strong>China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>) announced today that the <strong>Center for Drug Evaluation (CDE)<\/strong> of the <strong>National Medical Products Administration (NMPA)<\/strong> has granted a second <strong>Breakthrough Therapy Designation (BTD)<\/strong> to its bispecific antibody\u2011drug conjugate (ADC), <strong>izalontamab brengitecan (iza\u2011bren, code\u202fBL\u2011B01D1)<\/strong>. The new designation covers patients with <strong>unresectable locally advanced or metastatic urothelial carcinoma (UC)<\/strong> who have progressed after platinum\u2011based chemotherapy and PD\u20111\/PD\u2011L1 inhibitor therapy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-izalontamab-brengitecan-brings\">What Izalontamab Brengitecan Brings<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011class, EGFR\u00d7HER3 bispecific ADC<\/strong> \u2013 Combines dual antigen targeting with a potent cytotoxic payload, offering a novel mechanism of action in urothelial cancer.<\/li>\n\n\n\n<li><strong>Phase\u202f3\u2011ready<\/strong> \u2013 The only bispecific ADC in Phase\u202f3 development, currently enrolled in <strong>over 40 clinical trials<\/strong> across China and the United States.<\/li>\n\n\n\n<li><strong>Strategic partnership<\/strong> \u2013 Co\u2011developed with <strong>Bristol\u2011Myers\u202fSquibb (BMS)<\/strong>, which holds global development and commercialization rights outside mainland China.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regulatory-milestones\">Regulatory Milestones<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>December\u202f2023<\/strong> \u2013 Biokin signed a licensing and collaboration agreement with BMS, expanding izalontamab brengitecan\u2019s reach worldwide.<\/li>\n\n\n\n<li><strong>Prior BTD<\/strong> \u2013 The ADC previously received Breakthrough Therapy Designation for <strong>platinum\u2011resistant recurrent epithelial ovarian cancer, fallopian\u2011tube cancer, and primary peritoneal cancer<\/strong>.<\/li>\n\n\n\n<li><strong>Current BTD<\/strong> \u2013 The new designation for urothelial carcinoma underscores the drug\u2019s expanding therapeutic portfolio and the NMPA\u2019s commitment to accelerating high\u2011impact oncology therapies.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Edge<\/strong> \u2013 The BTD accelerates clinical development and potential market entry, positioning izalontamab brengitecan against emerging ADCs and immunotherapies in urothelial cancer.<\/li>\n\n\n\n<li><strong>Investor Appeal<\/strong> \u2013 Biokin\u2019s partnership with BMS and multiple BTDs enhance its valuation prospects, appealing to both domestic and international investors.<\/li>\n\n\n\n<li><strong>Strategic Growth<\/strong> \u2013 Success in the U.S. and China markets could catalyze further collaboration with global oncology leaders and drive revenue growth for both Biokin and BMS.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the Center for Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42337,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,151,34,857],"class_list":["post-42335","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-breakthrough-therapy","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted a second Breakthrough Therapy Designation (BTD) to its bispecific antibody\u2011drug conjugate (ADC), izalontamab brengitecan (iza\u2011bren, code\u202fBL\u2011B01D1). The new designation covers patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who have progressed after platinum\u2011based chemotherapy and PD\u20111\/PD\u2011L1 inhibitor therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42335\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted a second Breakthrough Therapy Designation (BTD) to its bispecific antibody\u2011drug conjugate (ADC), izalontamab brengitecan (iza\u2011bren, code\u202fBL\u2011B01D1). The new designation covers patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who have progressed after platinum\u2011based chemotherapy and PD\u20111\/PD\u2011L1 inhibitor therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42335\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-26T06:00:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-26T06:00:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42335#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42335\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma\",\"datePublished\":\"2025-09-26T06:00:56+00:00\",\"dateModified\":\"2025-09-26T06:00:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42335\"},\"wordCount\":300,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42335#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2603.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Breakthrough therapy\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42335#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42335\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42335\",\"name\":\"Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42335#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42335#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2603.webp\",\"datePublished\":\"2025-09-26T06:00:56+00:00\",\"dateModified\":\"2025-09-26T06:00:57+00:00\",\"description\":\"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted a second Breakthrough Therapy Designation (BTD) to its bispecific antibody\u2011drug conjugate (ADC), izalontamab brengitecan (iza\u2011bren, code\u202fBL\u2011B01D1). The new designation covers patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who have progressed after platinum\u2011based chemotherapy and PD\u20111\\\/PD\u2011L1 inhibitor therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42335#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42335\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42335#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42335#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted a second Breakthrough Therapy Designation (BTD) to its bispecific antibody\u2011drug conjugate (ADC), izalontamab brengitecan (iza\u2011bren, code\u202fBL\u2011B01D1). The new designation covers patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who have progressed after platinum\u2011based chemotherapy and PD\u20111\/PD\u2011L1 inhibitor therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42335","og_locale":"en_US","og_type":"article","og_title":"Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma","og_description":"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted a second Breakthrough Therapy Designation (BTD) to its bispecific antibody\u2011drug conjugate (ADC), izalontamab brengitecan (iza\u2011bren, code\u202fBL\u2011B01D1). The new designation covers patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who have progressed after platinum\u2011based chemotherapy and PD\u20111\/PD\u2011L1 inhibitor therapy.","og_url":"https:\/\/flcube.com\/?p=42335","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-26T06:00:56+00:00","article_modified_time":"2025-09-26T06:00:57+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42335#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42335"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma","datePublished":"2025-09-26T06:00:56+00:00","dateModified":"2025-09-26T06:00:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42335"},"wordCount":300,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42335#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2603.webp","keywords":["ADC \/ XDC","Biokin Pharmaceutical","Breakthrough therapy","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42335#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42335","url":"https:\/\/flcube.com\/?p=42335","name":"Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42335#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42335#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2603.webp","datePublished":"2025-09-26T06:00:56+00:00","dateModified":"2025-09-26T06:00:57+00:00","description":"China\u2011based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted a second Breakthrough Therapy Designation (BTD) to its bispecific antibody\u2011drug conjugate (ADC), izalontamab brengitecan (iza\u2011bren, code\u202fBL\u2011B01D1). The new designation covers patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who have progressed after platinum\u2011based chemotherapy and PD\u20111\/PD\u2011L1 inhibitor therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42335#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42335"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42335#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2603.webp","width":1080,"height":608,"caption":"Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42335#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42335"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42335\/revisions"}],"predecessor-version":[{"id":42338,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42335\/revisions\/42338"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42337"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}